SRRK
Scholar Rock Holding Corporation
NASDAQ · Healthcare · Biotechnology · US
$55.33
−1.09%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | 33.2M |
| Cost of Revenue | 97.7M | 208.4M | 1.9M | 2.8M | 123.0M |
| Gross Profit | (97.7M) | (208.4M) | (1.9M) | (2.8M) | (89.9M) |
| Operating Expenses | |||||
| R&D Expense | 207.4M | 208.4M | 182.6M | 119.1M | 124.4M |
| SG&A Expense | 199.0M | 176.2M | 67.5M | 49.4M | 42.6M |
| General & Admin Expense | 199.0M | 176.2M | — | — | 42.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (97.4M) | (208.4M) | — | — | (122.5M) |
| Total Operating Expenses | 309.0M | 176.2M | 250.1M | 168.5M | 44.5M |
| Cost and Expenses | 406.4M | 384.6M | 252.1M | 171.3M | 167.6M |
| Operating Income (EBIT) | (406.4M) | (384.6M) | (252.1M) | (171.3M) | (134.4M) |
| Non-Operating | |||||
| Interest Income | 13.3M | 13.9M | 12.7M | — | — |
| Interest Expense | 10.7M | 6.9M | 6.8M | — | — |
| Net Interest Income | 2.6M | 7.0M | 5.8M | — | — |
| Other Non-Op Income/Expense | (2.2M) | 6.7M | 5.8M | 5.5M | (132.0K) |
| Non-Operating Income (excl Interest) | (8.5M) | (13.6M) | (12.6M) | (5.5M) | (1.9M) |
| EBT (Pre-Tax Income) | (408.6M) | (377.9M) | (246.3M) | (165.8M) | (134.5M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (408.6M) | (377.9M) | (246.3M) | (165.8M) | (134.5M) |
| Earnings from Cont. Ops | (408.6M) | (377.9M) | (246.3M) | (165.8M) | (134.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (408.6M) | (377.9M) | (246.3M) | (165.8M) | (134.5M) |
| Per Share | |||||
| Basic EPS | ($3.31) | ($3.29) | ($2.47) | ($1.99) | ($2.21) |
| Diluted EPS | ($3.31) | ($3.29) | ($2.47) | ($1.99) | ($2.21) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.56 |
| Shares | |||||
| Basic Shares Outstanding | 130.6M | 114.7M | 99.8M | 76.0M | 59.6M |
| Diluted Shares Outstanding | 130.6M | 114.7M | 99.8M | 76.0M | 59.6M |
| Profitability Metrics | |||||
| EBITDA | (396.4M) | (369.4M) | (237.5M) | (162.9M) | (129.5M) |
| D&A | 1.5M | 1.7M | 1.9M | 2.8M | 3.0M |
| EBIT | (397.9M) | (371.0M) | (239.5M) | (165.8M) | (132.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026